The Use of CCTA for Pre-Planning PCI

Overview

This activity covers critical aspects of CCTA calcium analysis, the latest research in precise procedural planning, and a case study on balloon uncrossable lesions requiring calcium modification techniques. Faculty will discuss diagnostic procedures, imaging modalities, and management strategies, highlighting their advantages and limitations.

Faculty and Agenda

	Emmanouil Brilakis, MD, PhD, FSCAI Moderator		Yader Sandoval, MD, FSCAI Everything You Need to Know About How to Use CCTA for Planning PCI
	Carlos Collet, MD, PhD, FSCAI Moderator Precise Procedural and PCI Plan (P4) Research Update		Farouc Jaffer, MD, PhD, FSCAI CCTA Analysis of Calcium: What to Look for and What You Can Do About It
	Arasi Maran, MD, FSCAI Case: Why Balloon Uncrossable Lesions May Require a Combination of Calcium Modification Techniques

Acknowledgement of Commercial Support

This activity is supported by an unrestricted educational grant from Shockwave Medical.

Learning Objectives

At the conclusion of this initiative participants will be able to demonstrate the ability to: 

Explain the principles and technical aspects of CCTA imaging.
Describe the role of CCTA in the assessment of coronary artery disease and calcium modification and its relevance in pre-procedural planning for PCI.
Analyze the clinical evidence supporting the use of CCTA for PCI planning, including risk stratification and procedural outcomes.
Apply CCTA to management of difficult lesion subsets, including calcified lesions (and vulnerable plaque).

Disclosures

Individuals in control of content have disclosed the following relevant relationships with ineligible companies during the content development process for this activity. All potential conflicts are mitigated before the start of the activity.

PLANNERS 
Anthony Fletcher and Triston Smith: No relevant financial relationships with ineligible companies.

FACULTY 
Tayo Addo, Quinn Capers, Anthony Fletcher, Yolanda Hendley, and Triston Smith: No relevant financial relationships with ineligible companies.
Alaide Chieffo: Boehringer Ingelheim, Advisory Board. Abbott, Advisory Board.
Karol Watson: Amgen, Boehringer Ingelheim, Eli Lilly, Novartis, Consulting.

REVIEWER 
Andrew Klein: No financial relationships with ineligible companies.

SCAI STAFF
Robert Bartel and Laura Porter: No financial relationships with ineligible companies

Accredited Continuing Education Information

Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
SCAI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful Completion
Watch the content and complete the evaluation to obtain credit.

Activity Timeline
Record date: 4/23/2025
Publish date: 5/15/2025
Expiration date: 5/15/2028

Summary

Availability:

On-Demand

Expires on May 15, 2028

Cost:

Member: $0.00
Non-Member: $19.00
Fellow-In-Training: $0.00
Cardio Team Member: $0.00

Credit Offered:

1 CME Credit

1 ABIM-MOC Point

1 Participation Credit